FibroGen Inc. has announced the entry into a Third Amendment to its existing financing agreement with investment funds managed by Morgan Stanley Tactical Value. The amendment, dated July 14, 2025, involves a reduction in the minimum qualified cash balance that FibroGen is required to maintain in its U.S. deposit or securities accounts, lowering the amount from $22.5 million to $18.75 million. This amendment is part of an ongoing financing arrangement initially established on April 29, 2023, and managed by Wilmington Trust National Association as the administrative agent. The details of this amendment are documented in the full text filed as Exhibit 10.1 to the company's current report on Form 8-K.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.